Table 2 Change in weight and body fat according to treatment.

From: Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease

 

Probiotic (n = 30)

Placebo (n = 35)

Difference (p-value)

Baseline

3 months

*P

Baseline

3 months

*P

Weight (kg)

81.8 ± 13.6

81.2 ± 13.5

0.072

82.6 (79.3)

83.4 (79.5)

0.012

−1.35 (0.0029)

BMI (kg/m2)

30.0 ± 3.6

29.8 ± 3.6

0.047

30.1 (29.1)

30.4 (28.8)

0.024

−0.48 (0.0024)

Visceral fat (cm2)

146.1 (14.7)

144.3 (14.4)

0.730

158.35 ± 58.6

158.2 ± 59.5

0.992

−169.5 (0.7590)

Total fat mass (kg)

30.8(29.5)

29.95 ± 6.4

0.104

31.0 (28.7)

31.5 (30)

0.07

−1.25 (0.0282)

Total body fat (%)

37.9 ± 6.7

37.1 ± 6.3

0.146

37.3 ± 7.53

37.7 ± 7.31

0.260

−0.90 (0.0324)

Visceral fat grade

14.0 ± 3.7

13.6 ± 3.4

0.192

14.3 ± 4.55

14.9 ± 4.8

0.092

−1.12 (0.0297)

Right liver FF (%)

17.3 (16.1)

15.1 ± 7.7

0.053

14.7 (13.3)

15.3 (12.8)

0.272

−2.63 (0.0284)

Left liver FF (%)

15.2 (12.9)

13.1 ± 7.9

0.019

13.1(10.0)

13.6 (10.3)

0.302

−2.59 (0.0087)

Whole liver FF (%)

16.3 (15.0)

14.1 ± 7.7

0.032

13.9 (11.6)

14.4 (11.5)

0.255

−2.61 (0.0129)

Waist-hip ratio

0.94 ± 0.06

0.95 ± 0.05

0.239

0.96 ± 0.05

0.97 ± 0.06

0.113

−0.001 (0.9317)

CAP (dB/m)

313.4 ± 60.3

315.3 ± 42.3

0.859

310.0 ± 47.0

305.4 ± 47.0

0.569

5.69 (0.626)

Liver stiffness (kPa)

9.65 ± 16.2

6.17 ± 2.50

0.221

6.76 ± 3.42

6.18 ± 2.88

0.142

−3.39 (0.28)

  1. Data are expressed as median (interquartile range) with p values from Wilcoxon signed-rank test or mean difference with p value in parentheses.
  2. BMI: body mass index, FF: fat fraction. Abdominal fat and visceral fat area were measured with magnetic resonance imaging. Total fat mass and total body fat were measured with bio-impedance. *p < 0.05 by paired t-test.
Back to article page